Case report: Enfortumab vedotin induced refractory DKA and multi organ failure – a rare fatal adverse event

Case report: Enfortumab vedotin induced refractory DKA and multi organ failure – a rare fatal adverse event

There are very few therapeutic options to treat patients with locally advanced or metastatic Urothelial Cancer (UC). Enfortumab vedotin (EV) was recently approved by the FDA and has become a new therapeutic option for patients previously managed with conventional treatments. Despite its efficacy, EV...

Full description

Bibliographic Details
Main Authors: Astha Koolwal Kapoor, Carleton S. Ellis, Deepali Pandey, Derek B. Allison, Zin W. Myint
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
diabetes ketoacidosis
CRRT
insulin
enfortumab vedotin
maculopapular rash
liver failure
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1332478/full

Similar Items

Similar Items